TY - JOUR T1 - MAIT cell activation and dynamics associated with COVID-19 disease severity and outcome JF - medRxiv DO - 10.1101/2020.08.27.20182550 SP - 2020.08.27.20182550 AU - Tiphaine Parrot AU - Jean-Baptiste Gorin AU - Andrea Ponzetta AU - Kimia T. Maleki AU - Tobias Kammann AU - Johanna Emgârd AU - André Perez-Potti AU - Takuya Sekine AU - Olga Rivera-Ballesteros AU - the Karolinska COVID-19 Study Group AU - Elin Folkesson AU - Olav Rooyackers AU - Lars I. Eriksson AU - Anna Norrby-Teglund AU - Hans-Gustaf Ljunggren AU - Niklas K. Björkström AU - Soo Aleman AU - Marcus Buggert AU - Jonas Klingström AU - Kristoffer Strålin AU - Johan K. Sandberg Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20182550.abstract N2 - Severe COVID-19 is characterized by excessive inflammation of the lower airways. The balance of protective versus pathological immune responses in COVID-19 is incompletely understood. Mucosa-associated invariant T (MAIT) cells are antimicrobial T cells that recognize bacterial metabolites, and can also function as innate-like sensors and mediators of antiviral responses. Here, we investigated the MAIT cell compartment in COVID-19 patients with moderate and severe disease, as well as in convalescence. We show profound and preferential decline in MAIT cells in circulation of patients with active disease paired with strong activation, as well as significant MAIT cell enrichment and pro-inflammatory IL-17A bias in the airways. Unsupervised analysis identified MAIT cell CD69high and CXCR3low immunotypes associated with poor clinical outcome. MAIT cell levels normalized in the convalescent phase, consistent with dynamic recruitment to the tissues and subsequent release with disease resolution. These findings indicate that MAIT cells are engaged in the immune response against SARS-CoV-2 and suggest their involvement in COVID-19 immunopathogenesis.One sentence summary MAIT cells are strongly activated by SARS-CoV-2 infection in a manner associated with disease severity and outcome, they decline in blood, are enriched in the airways as a prominent IL-17A expressing subset, and dynamically recover in circulation during convalescence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants to J.K.S. from the Swedish Research Council (2016-03052), the Swedish Cancer Society (CAN 2017/777), the Swedish Heart-Lung Foundation (20180675), the Center for Innovative Medicine (20190732), and Karolinska Institutet. H.G.L. and the Karolinska COVID-19 study group was supported by the Knut and Alice Wallenberg foundation and Nordstjernan AB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority and all patients gave informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCurated flow cytometry data is available for exploration via the Karolinska COVID-19 Immune Atlas (homepage currently under construction). Other data are available on request from the corresponding author. ER -